

# Herbert Kuster

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/896315/publications.pdf>

Version: 2024-02-01

23  
papers

908  
citations

516710

16  
h-index

677142

22  
g-index

23  
all docs

23  
docs citations

23  
times ranked

1600  
citing authors

#	ARTICLE	IF	CITATIONS
1	Detecting Selection in the HIV-1 Genome during Sexual Transmission Events. <i>Viruses</i> , 2022, 14, 406.	3.3	1
2	The Interplay Between Replication Capacity of HIV-1 and Surrogate Markers of Disease. <i>Journal of Infectious Diseases</i> , 2022, 226, 1057-1068.	4.0	2
3	A Novel High Throughput, Parallel Infection Assay for Determining the Replication Capacities of 346 Primary HIV-1 Isolates of the Zurich Primary HIV-1 Infection Study in Primary Cells. <i>Viruses</i> , 2021, 13, 404.	3.3	3
4	HIV-1 integration sites in CD4+ T-cells during primary, chronic, and late presentation of HIV-1 infection. <i>JCI Insight</i> , 2021, 6, .	5.0	7
5	Evaluation of Broadly Neutralizing Antibody Sensitivity by Genotyping and Phenotyping for Qualifying Participants to HIV Clinical Trials. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 88, 61-69.	2.1	6
6	Widespread B cell perturbations in HIV-1 infection afflict naive and marginal zone B cells. <i>Journal of Experimental Medicine</i> , 2019, 216, 2071-2090.	8.5	22
7	Noninferiority of Simplified Dolutegravir Monotherapy Compared to Continued Combination Antiretroviral Therapy That Was Initiated During Primary Human Immunodeficiency Virus Infection: A Randomized, Controlled, Multisite, Open-label, Noninferiority Trial. <i>Clinical Infectious Diseases</i> , 2019, 69, 1489-1497.	5.8	19
8	Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. <i>Nature</i> , 2018, 561, 406-410.	27.8	47
9	Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. <i>Journal of Experimental Medicine</i> , 2018, 215, 1589-1608.	8.5	29
10	Determinants of HIV-1 broadly neutralizing antibody induction. <i>Nature Medicine</i> , 2016, 22, 1260-1267.	30.7	133
11	Monocyte-derived macrophages exhibit distinct and more restricted HIV-1 integration site repertoire than CD4+ T cells. <i>Scientific Reports</i> , 2016, 6, 24157.	3.3	21
12	Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs. <i>Retrovirology</i> , 2016, 13, 62.	2.0	45
13	Gut commensal microbes do not represent a dominant antigenic source for continuous CD4 <sup>+</sup> T cell activation during HIV-1 infection. <i>European Journal of Immunology</i> , 2015, 45, 3107-3113.	2.9	1
14	A Novel Acute Retroviral Syndrome Severity Score Predicts the Key Surrogate Markers for HIV-1 Disease Progression. <i>PLoS ONE</i> , 2014, 9, e114111.	2.5	17
15	Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Diversity and Tropism in 145 Patients With Primary HIV-1 Infection. <i>Clinical Infectious Diseases</i> , 2011, 53, 1271-1279.	5.8	84
16	Early Antiretroviral Therapy During Primary HIV-1 Infection Results in a Transient Reduction of the Viral Setpoint upon Treatment Interruption. <i>PLoS ONE</i> , 2011, 6, e27463.	2.5	46
17	HIV-1 transmission after cessation of early antiretroviral therapy among men having sex with men. <i>Aids</i> , 2010, 24, 1177-1183.	2.2	62
18	In Vivo and In Vitro Escape from Neutralizing Antibodies 2G12, 2F5, and 4E10. <i>Journal of Virology</i> , 2007, 81, 8793-8808.	3.4	85

#	ARTICLE	IF	CITATIONS
19	Low Human Immunodeficiency Virus Envelope Diversity Correlates with Low In Vitro Replication Capacity and Predicts Spontaneous Control of Plasma Viremia after Treatment Interruptions. <i>Journal of Virology</i> , 2005, 79, 9026-9037.	3.4	40
20	Quantification of infectious HIV-1 plasma viral load using a boosted in vitro infection protocol. <i>Virology</i> , 2004, 326, 113-129.	2.4	76
21	Humoral immunity to HIV-1: kinetics of antibody responses in chronic infection reflects capacity of immune system to improve viral set point. <i>Blood</i> , 2004, 104, 1784-1792.	1.4	46
22	Human Immunodeficiency Virus Type 1 Fitness Is a Determining Factor in Viral Rebound and Set Point in Chronic Infection. <i>Journal of Virology</i> , 2003, 77, 13146-13155.	3.4	54
23	Residual Cell-Associated Unspliced HIV-1 Rna in Peripheral Blood of Patients on Potent Antiretroviral Therapy Represents Intracellular Transcripts. <i>Antiviral Therapy</i> , 2002, 7, 91-103.	1.0	62